Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M08D1 in Advanced Melanoma and Solid Tumors
NCT07841925Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M08D1 in melanoma, solid tumor, sponsored by Biokin Pharmaceutical. Started Oct 2026; status: recruiting.
02
Drugs
BL-M08D1
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT07841925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841925.